← Back

Wire · opportunities

Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP Trial

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

Recursion Pharmaceuticals has agreed with the FDA on a primary composite endpoint for its Phase III global registrational trial of REC-4881 in familial adenomatous polyposis (FAP), targeting patients post-colon removal. The trial starts in 2027 and will measure time to clinically significant events including polyps excision, surgeries, cancer, or death.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a clearer path to market with FDA-aligned endpoints for FAP treatment, enabling clinical focus on relevant patient events. Plan your trial design and investor communications now to match evolving regulatory expectations.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-agreementphase-iii-trialrare-diseaseclinical-endpointbiotech